Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine

Hepatology

Volumn 57, Issue 4, 2013, Pages 1303-1313

  Beaumont, Elodie ^a   Patient, Romuald ^a   Hourioux, Christophe ^a   Dimier Poisson, Isabelle ^a   Roingeard, Philippe ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; HETERODIMER; HYBRID PROTEIN; MIFAMURTIDE; NEUTRALIZING ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL SURFACE; CHO CELL; EXPERIMENTAL RABBIT; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; VACCINATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; IMMUNITY, HUMORAL; PROTEIN FOLDING; RABBITS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 84876114944     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26132     Document Type: Article

References (41)

1. Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9.
2. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc of the Natl Acad Sci U S A 2010; 107: 14757-14762.
3. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56( Suppl 1):S88-S100.
4. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.
5. Lucas M, Ulsenheimer A, Pfafferot K, Heeg MHJ, Gaudieri S, Grüner N, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One 2007; 2: e649.
6. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J virol 2004; 78: 1575-1581.
7. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-324.
8. Pape G, Gerlach T, Diepolder H, Grüner N, Jung MC, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J viral hepat 1999; 6: 36-40.
9. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc of the Natl Acad Sci U S A 2007; 104: 6025.
10. Choo Q, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc of the Natl Acad Sci U S A 1994; 91: 1294.
11. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961-966.
12. Meunier J-C, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204: 1186-1190.
13. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28: 6367-6373.
14. Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, et al. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 1998; 273: 32088.
15. Sominskaya I, Alekseeva E, Skrastina D, Mokhonov V, Starodubova E, Jansons J, et al. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol immunol 2006; 43: 1941-1952.
16. Garrone P, Fluckiger A-C, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3: 94ra71.
17. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-180.
18. Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N Biotechnol 2009; 25: 226-234.
19. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2007; 14: 25-27.
20. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 2012; 109: 6205-6210.
21. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174: 1168.
22. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
23. Gottwein JM, Scheel TKH, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49: 364-377.
24. Bartosch B, Dubuisson J, Cosset F-L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
25. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005; 41: 265-274.
26. Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474: S18-S19.
27. Edwards VC, Tarr AW, Urbanowicz RA, Ball JK. The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012; 93: 1-19.
28. Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001; 75: 2130-2141.
29. Michel ML, Mancini M, Sobczak E, Favier V, Guetard D, Bahraoui EM, et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc Natl Acad Sci USA 1988; 85: 7957.
30. Keck Z-Y, Li T-K, Xia J, Gal-Tanamy M, Olson O, Li SH, et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 2008; 82: 6061-6066.
31. Meunier J-C, Russell RS, Goossens V, Priem S, Walter H, Depla E, et al. Isolation and Characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol 2007; 82: 966-973.
32. Leroux-Roels G, Batens A-H, Desombere I, Van Den Steen B, Vander Stichele C, Maertens G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005; 1: 61-65.
33. Keck ZY, Sung VMH, Perkins S, Rowe J, Paul S, Liang TJ, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J virol 2004; 78: 7257-7263.
34. Brazzoli M, Helenius A, Foung SKH, Houghton M, Abrignani S, Merola M. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology 2005; 332: 438-453.
35. Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004; 22: 3080-3086.
36. Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JAR, Priem S, et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 2011; 204: 837-844.
37. Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008; 135: 1719-1728.e1.
38. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 1994; 68: 6147-6160.
39. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010; 84: 10159-10168.
40. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007; 25: 7773-7784.
41. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8: 379-386.